Backed by more than 16 years of experience and research, EndoTool® IV has been proven to increase accuracy, reduce guesswork and bring even the most challenging patients back into a safe blood glucose range.
Glycemic events can propel patients into an expensive, prolonged and health-deteriorative cycle—EndoTool IV helps hospital systems manage this.
EndoTool IV’s feedback-controlled algorithm calculates each insulin dosing recommendation using 11 patient-specific factors. This allows bedside clinicians to streamline their care and provide even the most challenging patients with personalized insulin doses from the very beginning of treatment. With EndoTool IV, patients achieve glycemic control safely and quickly, meaning they are less likely to acquire subsequent infections, they avoid spending additional time in expensive critical care units and their overall hospital length of stay is reduced.
The Safest in Personalized and Predictive Insulin Dosing Monarch Medical Technologies, the maker of the EndoTool® Glucose Management System, is the leading provider of precision insulin dosing technology for improved patient outcomes.